You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PCI-32765

Showing 26 - 50 of 1,765
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome Trial in

Completed
  • Myelodysplastic Syndrome
  • +4 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 11, 2021

Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
Jul 6, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory

Suspended
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
Apr 29, 2022

Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
May 3, 2022

Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Bcl-2 Inhibitor GDC-0199
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Oct 29, 2021

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome Trial

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +2 more
  • Biopsy
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

Completed
  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell
  • ABT-199 and Ibrutinib Combination
  • Duarte, California
  • +3 more
May 22, 2022

Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Sacramento (Ibrutinib, Nivolumab)

Completed
Has Results
  • Metastatic Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Feb 8, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma Trial in

Active, not recruiting
  • Contiguous Stage II Mantle Cell Lymphoma
  • +4 more
  • Chicago, Illinois
  • +4 more
Apr 30, 2021

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
Feb 2, 2023

Classical Hodgkin Lymphoma Trial in Atlanta, Columbus (drug, other, biological)

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Atlanta, Georgia
  • +1 more
Mar 23, 2021

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

Lung Cancer Trial in Houston (Ibrutinib)

Completed
  • Lung Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 21, 2021

Metastatic Malignant Solid Tumor Trial in Columbus (drug, other, biological)

Unknown status
  • Metastatic Malignant Solid Neoplasm
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 22, 2021

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Indolent Non-Hodgkin Lymphoma Trial in München (Ibrutinib, GA 101)

Active, not recruiting
  • Indolent Non-Hodgkin Lymphoma
  • München, Bavaria, Germany
    Klinikum der Universität München
May 6, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (biological, drug, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Palo Alto (Ibrutinib, Laboratory

Unknown status
  • Acute Biphenotypic Leukemia
  • +4 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jan 28, 2021

Multiple Myeloma Trial in Canada, United States (Ibrutinib, Carfilzomib, Dexamethasone)

Completed
Has Results
  • Multiple Myeloma
  • Duarte, California
  • +16 more
Nov 24, 2021

DLBCL Unclassifiable Trial in Houston (Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma Unclassifiable
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021